Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 2/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489075 | 1.00 | RORC (0.57) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL5923781 | 1.00 | RORC (0.57) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL5923783 | 1.00 | RORC (0.57) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL29960333 | 0.92 | RORC (0.55) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL2242108 | 0.90 | GPR119 (0.54) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL2246047 | 0.90 | GPR119 (0.54) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL407256 | 0.90 | GPR119 (0.54) | RORCGPR119TACR1USP30JAK2 | |
| SCHEMBL23951332 | 0.88 | RORC (0.64) | RORCGPR119TACR1USP30KDM4E | |
| SCHEMBL3991383 | 0.88 | RORC (0.64) | RORCGPR119TACR1USP30KDM4E | |
| SCHEMBL17172484 | 0.88 | RORC (0.64) | RORCGPR119TACR1USP30KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | RORC 2424/4885GPR119 218/4885TACR1 6/4885 |
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | RORC 1418/4885GPR119 522/4885TACR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.